QTREX CTO sells 50,000 shares at $3 each

QTREX Quantum Ltd. Chief Technology Officer Daniella Yechezkely Hayon reported an open-market sale of 50,000 Ordinary Shares at $3.00 per share.

Rhea-AI Filing Summary

QTREX Quantum Ltd. Chief Technology Officer Daniella Yechezkely Hayon reported an open-market sale of 50,000 Ordinary Shares at $3.00 per share. The sale followed the vesting of Restricted Share Units, where each RSU converted into one Ordinary Share. After this transaction, she directly holds 780,000 Ordinary Shares.

Insider Trade Summary

Net Seller: 50,000 shares

Net Sell 1 txn

Insider Yechezkely Hayon Daniella

Role Chief Technology Officer

Sold 50,000 shs ($150K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	50,000	$3.00	$150K

Holdings After Transaction: Ordinary Shares — 780,000 shares (Direct)

Footnotes (1)

1. F1. Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold.

Key Figures

Shares sold: 50,000 shares Sale price: $3.00 per share Shares held after transaction: 780,000 shares +2 more

5 metrics

Shares sold 50,000 shares Open-market sale of Ordinary Shares

Sale price $3.00 per share Price for Ordinary Shares sold on 2026-05-29

Shares held after transaction 780,000 shares Direct ownership following the sale

Transaction date 2026-05-29 Date of reported open-market sale

Transaction code S Sale in open market or private transaction

Key Terms

Restricted Share Units ("RSUs"), open-market sale, Ordinary Shares, vesting, +1 more

5 terms

Restricted Share Units ("RSUs") financial

"Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan..."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"the underlying Ordinary Shares received were then sold."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vesting financial

"Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Insense Medical 2019 Plan financial

"RSUs granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did QTREX Quantum (QTEX) report?

QTREX Quantum reported that its CTO, Daniella Yechezkely Hayon, sold 50,000 Ordinary Shares at $3.00 per share. This open-market transaction was disclosed in a Form 4 insider filing with post-transaction direct ownership of 780,000 shares.

Who is the insider involved in the latest QTREX Quantum Form 4?

The insider is Daniella Yechezkely Hayon, Chief Technology Officer of QTREX Quantum Ltd. She reported an open-market sale of 50,000 Ordinary Shares and now directly holds 780,000 shares following this transaction disclosed in the Form 4 filing.

How many QTREX Quantum shares did the CTO sell and at what price?

The CTO sold 50,000 Ordinary Shares of QTREX Quantum at $3.00 per share. This open-market sale reduced her holdings to 780,000 directly owned shares, as shown in the Form 4 insider transaction summary.

What is Daniella Yechezkely Hayon’s QTREX Quantum shareholding after the sale?

After the reported transaction, Daniella Yechezkely Hayon directly owns 780,000 Ordinary Shares of QTREX Quantum. This reflects her position following the open-market sale of 50,000 shares at $3.00 per share reported in the Form 4.

How are RSUs related to the QTREX Quantum CTO’s share sale?

The footnote explains that Restricted Share Units previously granted under the company’s 2019 plan vested into Ordinary Shares. Those underlying Ordinary Shares received upon vesting were then sold, resulting in the reported 50,000-share open-market sale.

Was the QTREX Quantum CTO’s transaction a buy or sell?

The transaction was a sell. The Form 4 identifies it with code “S” and describes it as an open-market sale of 50,000 Ordinary Shares at $3.00 per share, leaving the CTO with 780,000 directly owned shares afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/02/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yechezkely Hayon Daniella

(Last) (First) (Middle)

2 HA-TIDHAR ST.

(Street)

RA'ANANA 4366504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
QTREX Quantum Ltd. [ QTEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/29/2026		S		50,000(1)	D	$3	780,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Following the vesting of the Restricted Share Units ("RSUs") granted under Qtrex Quantum Ltd.'s Insense Medical 2019 Plan, with each RSU representing the right to receive, following vesting, one ordinary share, no par valuer per share (the "Ordinary Shares"), the underlying Ordinary Shares received were then sold.

	/s/ Daniella Yechezkely Hayon	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)